Aberdeen Group’s Kura Oncology KURA Stock Holding History

Aberdeen Group’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$8.44M	Buy	+788,361	New	+$8.82M	0.01%	688

Other funds holding KURA

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

OP Asset Management Helsinki $11.8B AUM 34.59% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Aberdeen Group's KURA Position: Q3 2026 in Review

Aberdeen Group opened a new position in Kura Oncology (KURA) in Q3 2026: 788,361 shares worth $8.44M. The stake represents 0.01% of the portfolio and ranks #688 among its holdings.

84 funds tracked by Wall St. Rank hold KURA as of Q3 2026.

Aberdeen Group held 788,361 shares of Kura Oncology worth $8.44M as of Q3 2026.
Kura Oncology was a new Aberdeen Group position in Q3 2026.
Kura Oncology made up 0.01% of Aberdeen Group's portfolio in Q3 2026, its #688 holding.
84 funds tracked by Wall St. Rank held Kura Oncology as of Q3 2026.

Based on Aberdeen Group's 13F filing for Q3 2026, filed 6 Nov 2026.